Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib

被引：2
|
作者：
Huang Yi-sheng [1 ]
Huang Biao [2 ]
Wu Yi-long [1 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Gen Hosp, Dept Radiol, Guangzhou 510080, Guangdong, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2011年 / 124卷 / 22期
关键词：
gefitinib; leukoencephalopathy; radiosensitizing; non-small cell lung cancer; RECEPTOR-TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; RADIATION; BRAIN; INHIBITOR; NEUROTOXICITY; CHEMOTHERAPY; METHOTREXATE; RADIOTHERAPY; SURVIVAL;
D O I：
10.3760/cma.j.issn.0366-6999.2011.22.043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The present case is a patient with advanced non-small cell lung cancer (NSCLC) who developed leukoencephalopathy following radiotherapy and gefitinib treatments. There are rarely reports of such incidences because the median survival period of advanced NSCLC is only ten months. The features of leukoencephalopathy in this case were atypical for radiation leukoencephalopathy, so it was suspected that the leukoencephalopathy was associated with gefitinib. Chin Med J 2011;124(22):3834-3837
引用
收藏
页码：3834 / 3837
页数：4
相关论文
共 50 条
  • [1] Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib
    HUANG YishengHUANG Biao and WU Yilong Guangdong Lung Cancer Institute Department of RadiologyGuangdong General Hospital and Guangdong Academy of Medical SciencesGuangzhou Guangdong China
    中华医学杂志(英文版), 2011, (22) : 3834 - 3837
  • [2] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [3] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [4] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [5] Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis
    Bersanelli, Melissa
    Tiseo, Marcello
    Artioli, Fabrizio
    Lucchi, Leonardo
    Ardizzoni, Andrea
    ANTICANCER RESEARCH, 2014, 34 (06) : 3185 - 3188
  • [6] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [7] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [8] Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer
    Araya, Tomoyuki
    Kasahara, Kazuo
    Demura, Yoshiki
    Matsuoka, Hiroki
    Nishitsuji, Masaru
    Nishi, Koichi
    LUNG CANCER, 2013, 80 (03) : 344 - 346
  • [9] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [10] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
12345